Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This study consist of 4-months induction first-line chemotherapy with the G.O.N.O. FOLFOXIRI
regimen plus bevacizumab followed by maintenance with bevacizumab or bevacizumab plus
metronomic chemotherapy (with capecitabine and cyclophosphamide) in mCRC patients.
The main objective of this study is to preliminarily evaluate the potential effects of the
combination of a metronomic chemotherapy with capecitabine and cyclophosphamide to
maintenance bevacizumab on pharmacodynamic and clinical parameters among mCRC patients.